VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EORTC CLTF 2021 | ALCANZA: brentuximab vedotin improves ORR and PFS in CTCL

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, talks on the findings of the randomized Phase III ALCANZA trial (NCT01578499) of brentuximab vedotin versus physician’s choice of methotrexate or bexarotene in patients with CD30+ cutaneous T-cell lymphoma (CTCL). Prof. Scarisbrick reports that 120 patients were enrolled. The overall response rate and progression-free survival was found to be significantly higher amongst patients receiving brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter